Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:CORT News 16 December 2025 - 2 January 2026

Corcept Therapeutics (CORT) stock rebounds today after FDA setback — here’s what investors are watching next

Corcept Therapeutics (CORT) stock rebounds today after FDA setback — here’s what investors are watching next

NEW YORK, January 2, 2026, 2:30 PM ET — Regular session Corcept Therapeutics Incorporated shares were up 5.7% at $36.77 on Friday afternoon, after a sharp selloff earlier in the week tied to a U.S. regulatory setback for its experimental drug relacorilant. The bounce matters because the FDA’s decision hit what investors had seen as a key growth driver beyond Corcept’s marketed therapy, and it reset expectations for how quickly relacorilant can reach patients in the company’s lead endocrine indication. A complete response letter is the FDA’s notice that a drug application cannot be approved as filed. For investors, it
2 January 2026
·····
Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

NEW YORK, January 1, 2026, 13:41 ET — Market closed Vanda Pharmaceuticals’ FDA win in motion sickness set the tone for outsized, stock-specific swings in healthcare shares as Wall Street paused for the New Year’s Day holiday. U.S. stock markets were closed Thursday. Nasdaq The moves matter because regulatory calls can dominate small-cap biotech even when the broader healthcare sector trades like a defensive corner of the market. Investors also head into January watching how rates and earnings guidance reshape valuations after thin year-end trading. In Wednesday’s final session of 2025, the Health Care Select Sector SPDR Fund (XLV) fell
1 January 2026
······
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

NEW YORK, January 1, 2026, 10:45 ET — Market closed. Corcept Therapeutics Inc (CORT) shares last ended Wednesday down 50.4% at $34.80 after the company said U.S. regulators were not ready to approve its drug relacorilant for a form of high blood pressure linked to hypercortisolism. U.S. stock markets are shut on Thursday for New Year’s Day. HCPLive The selloff matters because relacorilant was the company’s key near-term bet to broaden its commercial base beyond its current product, and the FDA’s response forces investors to reassess both timing and risk. It also sharpens focus on Corcept’s oncology program. In the
1 January 2026
·····
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

NEW YORK, January 1, 2026, 04:13 ET — Market closed Corcept Therapeutics Incorporated shares last closed down 50.4% at $34.80 on Wednesday. Yahoo Finance The selloff followed news that the U.S. drug regulator will not approve relacorilant in its current form for an expanded use tied to a rare hormonal disorder. The decision matters now because relacorilant was the company’s near-term bid to broaden its cortisol-modulation franchise beyond its existing product line, and investors had been bracing for a pivotal regulatory readout into year-end. A setback at the FDA can reset timelines and raise costs, forcing Wall Street to reprice
1 January 2026
·····
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

NEW YORK, December 31, 2025, 18:31 ET — After-hours Corcept Therapeutics Inc shares sank about 50% in after-hours trading on Wednesday after the U.S. Food and Drug Administration declined to approve its oral drug relacorilant for a Cushing’s-related hypertension use. The stock was last at $34.80, down $35.39 from the prior close. Reuters The decision hits at a key moment for Corcept, which investors have looked to relacorilant to expand the company’s business beyond its marketed drug Korlym. A regulatory setback for relacorilant raises the risk that Corcept’s next growth driver takes longer—and costs more—to reach the market. Reuters Corcept
1 January 2026
····
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

NEW YORK, December 31, 2025, 13:58 ET — Regular session Shares of Corcept Therapeutics Incorporated (CORT.O) sank nearly 50% on Wednesday after the U.S. Food and Drug Administration issued a complete response letter for the company’s relacorilant application in hypertension secondary to hypercortisolism, also known as Cushing’s syndrome. The stock was down 49.7% at $35.31 in afternoon trading. Nasdaq The decision lands at a sensitive moment for investors who had been looking to relacorilant as the company’s next product story in Cushing’s beyond its marketed therapy. “FDA’s request for additional data may require additional trials, significantly dimming Corcept’s outlook in
31 December 2025
·····
Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

NEW YORK, December 30, 2025, 13:14 ET — Regular session Corcept Therapeutics Inc shares fell 8.9% to $72.72 in early afternoon Nasdaq trading on Tuesday, after touching a session low of $72.26. The stock was last down $7.10 from Monday’s close, with about 897,000 shares traded. The decline comes as investors focus on Corcept on the day the U.S. Food and Drug Administration is due to decide on relacorilant, its experimental treatment for endogenous hypercortisolism, also known as Cushing’s syndrome. Under the Prescription Drug User Fee Act, or PDUFA, the FDA sets a target date for taking action on a
30 December 2025
·····
Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics Incorporated (NASDAQ: CORT) ended Tuesday, December 16, 2025, sharply lower after a strong 2025 run that had pushed expectations—and valuation—into the spotlight. Shares closed at $79.44, down $7.86 (about 9%) from the prior close, after trading as low as $78.84 on the day. The day’s narrative around Corcept Therapeutics stock wasn’t driven by a single blockbuster headline like an FDA decision or a clinical-trial halt. Instead, it was a classic “high-expectations” session: fresh sell-side coverage, valuation-focused commentary, and investors recalibrating risk ahead of a major FDA catalyst for relacorilant later this month. Below is a complete roundup of
16 December 2025
·····

Stock Market Today

Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

7 February 2026
BP shares closed up 1.9% at 478 pence Friday, just below a 52-week high, as the company continued buybacks ahead of next week’s results. BP repurchased 2.789 million shares on February 6. Oil prices firmed on geopolitical risk, with Brent at $68.05 a barrel, but sector outlook remains uncertain. Investors await BP’s earnings and dividend decision due Tuesday.
SSE share price near 2,510p as BoE rate-cut bets return; UK GDP and SSE updates ahead

SSE share price near 2,510p as BoE rate-cut bets return; UK GDP and SSE updates ahead

7 February 2026
SSE shares closed Friday at 2,510p, up 1.2%, with about 6.6 million shares traded. The company’s transmission arm secured over £6.9 million in Ofgem innovation funding for four projects. Investors adjusted UK rate-cut bets after a split Bank of England decision. SSE maintained 2025/26 earnings guidance and reported a 7% rise in renewables output.
Go toTop